Declining Pathology Reimbursement: Contracting Rates and Heightened Payer Scrutiny Increase Financial Pressure and Exposure

Declining pathology reimbursement hit a 2.4% reduction in the 2025 Medicare Physician Fee Schedule (MPFS) and a projected 44% drop (inflation-adjusted) for clinical pathology codes from 2004–2024. Organizations have faced consistent inflationary-adjusted decreases in pathology reimbursement rates over the last two decades.

Pathology billing is complex because it encompasses disease diagnosis and treatment across all medical specialties. It’s complicated to bill for varied services, and it’s even harder to get reimbursed in the face of mounting insurance company obstacles. Because pathology involves distinct, often complex CPT/ICD coding and, frequently, molecular diagnostics, specialized RCM improves pathology denial management and cash flow, and ensures compliance with regulatory requirements. Embracing digital transformation is one of the few remaining ways to take cost out of diagnostics

Here you can find the guidance you need to strengthen pathology revenue cycle management, reduce denial and pathology audit risk, and protect margins.

Why Pathology Reimbursement Is Declining🔗

Pathology leaders sharethat CMS fee schedule compression will be a headwind in coming years.

The College of American Pathologists (CAP) notes that recent Medicare Physician Fee Schedule policies—including an “efficiency adjustment” applied to many non–time-based service. That means reduced payment for a broad range of pathology codes, even where headline conversion factor changes appear modest.

CAP communication on the 2026 schedule highlights that while pathologists see a small net positive update on paper, a 2.5% efficiency adjustment and practice-expense changes can erode pathology reimbursement rates at the code level. Those providing common pathology services are particularly at risk.

These factors are contributing to lower reimbursements:

• Commercial plans pushing for lower contracted rates, tighter utilization controls, and more aggressive payment integrity programs.
• Increased payer scrutiny regarding advanced and molecular diagnostics - this attention results indenials, requests for information, and post-payment reviews.
• Minor coding variances that produce outsized payment shortfalls - at the claim level, modifier-driven reimbursement pressure and bundling rules increase the risk of revenue leakage.
• Tightening medical-necessity criteria and complex bundling logic - more pathology services risk being downcoded, bundled, or denied outright. To maintain margins, documentation and coding must be perfectly aligned with payer rules.

Heightened Pathology Payer Scrutiny and Pathology Audit Risk🔗

Payer scrutiny is escalating across both pre- and post-payment workflows. Payers increasingly use pre-payment edits to flag high-cost or high-variability pathology services for additional review. They then demand extra documentation or clarifying codes before payment is released.

Post-payment audits are also rising: MDaudit benchmark data cited in industry coverage shows a double-digit increase in denied dollars and a 30% increase in at-risk audit dollars per customer in 2025. This finding highlights a more assertive audit posture from both commercial and government payers.

Further, documentation demands have grown. More denials are tied to information requests or medical necessity. Payers implicate pathology frequently due to its dependence on clinical context from ordering providers.

Consider, too, that medical necessity reviews are particularly prominent in laboratory and pathology oversight. The OIG’s 2025 Work Plan includes focused review of Medicare payments for top clinical diagnostic laboratory. That means pathologists must carefully monitor volume, utilization patterns, and billing integrity to stay on top of declining pathology reimbursement rates. A forthcoming laboratory compliance program from OIG, combined with DOnd OIG commentary on laboratory risk areas, underscores that reference labs, genetic testing, and complex diagnostics will remain key focus areas. Pathology payer scrutiny raises exposure for pathology groups that lack robust compliance infrastructure.

Operational Risk to Pathology Groups🔗

Market and regulatory shifts are making it harder for pathology groups to reliably turn completed work into collected revenue. Declining revenue puts direct pressure on operations by forcing groups to cut staff, delay investments, and reduce services just to keep up with fixed costs and cash flow demands.

HFMA and other industry sources report denial rates from 10% to 14% of claims, with denial-related write-offs tripling since 2018 and coding-related denials increasing more than 100% over several years. For pathology, which often operates with high fixed costs and relatively thin per-unit margins, incremental increases in denials can quickly erode profitability.

In addition to rising denials, increased edits and documentation requests also lower reimbursement cycles. As more claims are pended for review or subjected to post-payment audits, days in A/R stretch, write-off risk grows, and pathology revenue cycle management becomes less predictable. This contributes to revenue volatility, especially when payer recoupments from prior periods hit current cash flow.

Compliance strain is also intensifying: pathology groups must keep pace with evolving OIG guidance for laboratories, payer coverage updates, and changing documentation standards, all while managing complex professional/technical, site-of-service, and modifier rules.

Today’s pathology groups must act on every preventable denial, delay, or underpayment to limit margin loss.

Professional and Technical Billing Complexity🔗

With each pathology bill subject to specific Medicare and commercial payer policies,even small variations in place of service, component split, or documentation detail can change how—and whether—the claim gets paid.

• Split-billing challenges arise when hospital-based technical components and independent pathology professional services get processed across different billing entities, systems, and contracts. In this environment, misalignment and denials commonly arise.
• Modifier accuracy is also critical, particularly for professional/technical splits, repeat procedures, and bundled services. Subtle modifier errors can trigger denials, underpayments, or retrospective audits.
• Contract modeling can also fall victim to billing complexity. Reimbursement may vary not only by CPT but by component, site of service, and payer-specific bundling logic.These subtleties make it challenging to forecast margin or identify systematic underpayments without sophisticated analytics.

Given these risks, underpayment detection becomes critical. Without automated comparison of remits to contracted terms, pathology groups may miss frequent small variances that accumulate into significant annual revenue leakage.

Protecting Margin in a High-Scrutiny Environment🔗

Protecting margin in this environment requires moving beyond basic billing to data-driven pathology revenue cycle management. Use these elements to create an efficient and optimized pathology RCM system:

• Real-time denial analytics can help pathology leaders see which payers, tests, sites, and modifiers are driving denials and rework. This visibility spawns targeted workflow fixes rather than broad, unfocused interventions.
• Contract performance monitoring ensures that actual payments match contract terms, surfacing underpayments by payer and service line. It also informs future contracting strategy.
• Underpayment analysis at scale is essential to recapture dollars lost to subtle fee schedule changes, misapplied edits, or incorrect bundling.
• Internal documentation audits and specialty-focused coding review programs help pathology groups validate that reports, ordering documentation, and codes support the billed services and medical necessity criteria that payers now scrutinize closely.
• Charge capture controls, reconciled across LIS, EMR, and billing platforms, help ensure that every accessioned specimen, ancillary test, and add-on service is appropriately billed, minimizing missed revenue that can’t be recovered after the fact.

By hardwiring these capabilities into daily operations, pathology groups can systematically plug revenue leaks and stabilize margins. In the face of declining pathology reimbursements, those that invest in data-driven, pathology revenue cycle management will be best positioned to protect profitability and reinvest in care.

Use Strategy--Not Volume--to Put a Stop to Declining Pathology Reimbursement🔗

Declining pathology reimbursement rates cannot be offset by volume alone.

In today’s high-scrutiny environment, pathology groups must proactively evaluate their reimbursement risk by examining denial patterns, contract performance, audit exposure, and underpayment trends. Medusind’s pathology RCM services support this effort by increasing profitability and efficiency. With 20+ years serving pathology organizations, we’ve found our average pathology claims get paid in less than 40 days. Overall, our clients collect up to 30% more cash, improve outstanding AR by 20%, and bring in 30% more patient collections.

Whether you are a pathologist, hematopathologist, cytopathologist, dermatopathologist, surgical pathologist, or neuropathologist, Medusind’s innovative technology and automation, along with our employees’ deep-industry expertise, ensure you optimize your revenue cycle.